278 related articles for article (PubMed ID: 15919746)
1. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
Efanov AM; Barrett DG; Brenner MB; Briggs SL; Delaunois A; Durbin JD; Giese U; Guo H; Radloff M; Gil GS; Sewing S; Wang Y; Weichert A; Zaliani A; Gromada J
Endocrinology; 2005 Sep; 146(9):3696-701. PubMed ID: 15919746
[TBL] [Abstract][Full Text] [Related]
2. Allosteric activators of glucokinase: potential role in diabetes therapy.
Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of β-cell genes and improved function in rodent islets following chronic glucokinase activation.
Gill D; Brocklehurst KJ; Brown HW; Smith DM
J Mol Endocrinol; 2011 Aug; 47(1):59-67. PubMed ID: 21571864
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
[TBL] [Abstract][Full Text] [Related]
5. Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells.
Wei P; Shi M; Barnum S; Cho H; Carlson T; Fraser JD
Diabetologia; 2009 Oct; 52(10):2142-50. PubMed ID: 19641898
[TBL] [Abstract][Full Text] [Related]
6. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism.
Futamura M; Hosaka H; Kadotani A; Shimazaki H; Sasaki K; Ohyama S; Nishimura T; Eiki J; Nagata Y
J Biol Chem; 2006 Dec; 281(49):37668-74. PubMed ID: 17028192
[TBL] [Abstract][Full Text] [Related]
7. Glucokinase activation is beneficial or toxic to cultured rat pancreatic islets depending on the prevailing glucose concentration.
Roma LP; Duprez J; Jonas JC
Am J Physiol Endocrinol Metab; 2015 Oct; 309(7):E632-9. PubMed ID: 26264555
[TBL] [Abstract][Full Text] [Related]
8. Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice.
Winzell MS; Coghlan M; Leighton B; Frangioudakis G; Smith DM; Storlien LH; Ahrén B
Eur J Pharmacol; 2011 Aug; 663(1-3):80-6. PubMed ID: 21586282
[TBL] [Abstract][Full Text] [Related]
9. Additive activation of glucokinase by the bifunctional enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and the chemical activator LY2121260.
Baltrusch S; Schmitt H; Brix A; Langer S; Lenzen S
Biochem Pharmacol; 2012 May; 83(9):1300-6. PubMed ID: 22305745
[TBL] [Abstract][Full Text] [Related]
10. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
[TBL] [Abstract][Full Text] [Related]
11. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
[TBL] [Abstract][Full Text] [Related]
13. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.
Fyfe MC; White JR; Taylor A; Chatfield R; Wargent E; Printz RL; Sulpice T; McCormack JG; Procter MJ; Reynet C; Widdowson PS; Wong-Kai-In P
Diabetologia; 2007 Jun; 50(6):1277-87. PubMed ID: 17415548
[TBL] [Abstract][Full Text] [Related]
14. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.
Doliba NM; Qin W; Najafi H; Liu C; Buettger CW; Sotiris J; Collins HW; Li C; Stanley CA; Wilson DF; Grimsby J; Sarabu R; Naji A; Matschinsky FM
Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E87-E102. PubMed ID: 21952036
[TBL] [Abstract][Full Text] [Related]
15. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
Haynes NE; Corbett WL; Bizzarro FT; Guertin KR; Hilliard DW; Holland GW; Kester RF; Mahaney PE; Qi L; Spence CL; Tengi J; Dvorozniak MT; Railkar A; Matschinsky FM; Grippo JF; Grimsby J; Sarabu R
J Med Chem; 2010 May; 53(9):3618-25. PubMed ID: 20405948
[TBL] [Abstract][Full Text] [Related]
16. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
Wang Z; Shi X; Zhang H; Yu L; Cheng Y; Zhang H; Zhang H; Zhou J; Chen J; Shen X; Duan W
Eur J Med Chem; 2017 Oct; 139():128-152. PubMed ID: 28800453
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation end products downregulate glucokinase in mice.
Jung H; Joo J; Jeon Y; Lee J; In J; Kim D; Kang E; Kim Y; Lim Y; Kang J; Choi J
Diabetes Metab Res Rev; 2011 Sep; 27(6):557-63. PubMed ID: 21538775
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ.
Lei L; Liu Q; Liu S; Huan Y; Sun S; Chen Z; Li L; Feng Z; Li Y; Shen Z
Metabolism; 2015 Oct; 64(10):1250-61. PubMed ID: 26189598
[TBL] [Abstract][Full Text] [Related]
19. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
[TBL] [Abstract][Full Text] [Related]
20. Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice.
Sreenan SK; Cockburn BN; Baldwin AC; Ostrega DM; Levisetti M; Grupe A; Bell GI; Stewart TA; Roe MW; Polonsky KS
Diabetes; 1998 Dec; 47(12):1881-8. PubMed ID: 9836519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
